Abstract:Polyglutamine (polyQ) diseases are a group of inherited neurodegenerative disorders caused by expanded cytosine-adenine-guanine (CAG) repeats encoding proteins with abnormally expanded polyglutamine tract. A total of nine polyQ disorders have been identified, including Huntington's disease, six spinocerebellar ataxias, dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy (SBMA). The diseases of this class are each considered rare, yet polyQ diseases constitute the largest group of monogenic neurodegenerative disorders. While each subtype of polyQ diseases has its own causative gene, certain pathologic molecular attributes have been implicated in virtually all of the polyQ diseases, including protein aggregation, proteolytic cleavage, neuronal dysfunction, transcription dysregulation, autophagy impairment, and mitochondrial dysfunction. Although animal models of polyQ disease are available helping to understand their pathogenesis and access disease-modifying therapies, there is neither a cure nor prevention for these diseases, with only symptomatic treatments available. In this paper, we analyze data from the CAS Content Collection to summarize the research progress in the class of polyQ diseases. We examine the publication landscape in the area in effort to provide insights into current knowledge advances and developments. We review the most discussed concepts and assess the strategies to combat these diseases. Finally, we inspect clinical applications of products against polyQ diseases with their development pipelines. The objective of this review is to provide a broad overview of the evolving landscape of current knowledge regarding the class of polyQ diseases, to outline challenges, and evaluate growth opportunities to further efforts in combating the diseases.

Nuclear Accumulation of Polyglutamine Disease Proteins and Neuropathology

Polyglutamine Protein Trafficking and Neurodegeneration

Transcriptional Dysregulation: A Therapeutic Target for Polyglutamine Diseases

Current Understanding on the Pathogenesis of Polyglutamine Diseases

Polyglutamine Expansion Alters the Dynamics and Molecular Architecture of Aggregates in Dentatorubropallidoluysian Atrophy

The Expanding Clinical Universe of Polyglutamine Disease.

Intracellular Degradation of Misfolded Proteins in Polyglutamine Neurodegenerative Diseases

Autophagy and Polyglutamine Disease

Nuclear poly-glutamine aggregates rupture the nuclear envelope and hinder its repair

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor.

Polyglutamine Expansion of Huntingtin Impairs Its Nuclear Export

Huntingtin-protein interactions and the pathogenesis of Huntington's disease.

Conformation Polymorphism of Polyglutamine Proteins

Upstream open reading frame with NOTCH2NLC GGC expansion generates polyglycine aggregates and disrupts nucleocytoplasmic transport: implications for polyglycine diseases

Expression of expanded GGC repeats within NOTCH2NLC causes behavioral deficits and neurodegeneration in a mouse model of neuronal intranuclear inclusion disease

Co-aggregation of polyglutamine (polyQ) proteins is mediated by polyQ-tract interactions and impairs cellular proteostasis

MicroRNAs and polyglutamine diseases]

Aggregation of Polyglutamine-Expanded Ataxin-3 Sequesters Its Specific Interacting Partners into Inclusions: Implication in a Loss-of-function Pathology

Endosome mediated nucleocytoplasmic trafficking and endomembrane allocation is crucial to polyglutamine toxicity